Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes

November 2013

Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.

Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.

In fact, nearly one in four diabetes patients take a gliptin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology bigger emphasis on preventing hospital admissions for heart failure
Diabetes Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes
Women's Health Reps will promote Brisdelle (BRIS-del) as a new nonhormonal treatment for hot flashes
Substance Use Disorder new approaches to managing alcohol dependence
Antithrombotics how to manage antiplatelet therapy in patients already taking anticoagulants
Pregnancy more questions about which cough, cold, and allergy meds to use during pregnancy and breastfeeding
Renal & Urology the best way to calculate creatinine clearance (CrCl) for dosing renally eliminated drugs
Contraceptives The new Minastrin 24 Fe and Lo Minastrin Fe (min-NASS-trin, norethindrone/ethinyl estradiol) are causing lots of confusion
Supplements whether the probiotic Cardioviva (CAR-dee-oh-VEE-vuh) lowers cholesterol
Dermatology Mirvaso (mer-VAY-soe) is a new brimonidine gel for rosacea
Pediatrics many parents exhibit signs of "fever phobia" and overuse antipyretics in their kids